Labcorp has entered into a definitive agreement to acquire Toxikon, a contract research organization delivering nonclinical testing services.
“Adding Toxikon underscores our commitment to nonclinical development and advances our capabilities for both drug development and medical device testing,” said Paul Kirchgraber, CEO of Labcorp Drug Development.
Toxikon is headquartered in Bedford, MA, with annual revenues of around $40 million.
